Chronic SIRT1 supplementation in diabetic mice improves endothelial function by suppressing oxidative stress.

"Conflict of interest: K.Y., S.V., A.A., T.L.-B., M.O.S., X.W., L.G., and A.X. have no conflicts of interest to report. S.K. has received funding from the Jubiläumsstiftung SwissLife, the Lindenhof Foundation, the Novartis Foundation for Medical-biological Research, the Swiss Heart Foundation, the Swiss Society of Cardiology, and the Theodor-Ida-Herzog-Egli Foundation, and materials and equipment from Roche Diagnostics outside the submitted work. Outside the submitted work, he has also been supported by the European Atherosclerosis Society, the European Society of Cardiology, the European Society of Clinical Investigation, Sphingotec GmbH, the 4TEEN4 Pharmaceuticals GmbH, and the PAM Theragnostics GmbH. T.F.L. has no conflicts related to this manuscript, but outside this work has received education and research grants from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Daichi Sankyo, Novartis, Sanofi, Servier, and Vifor. G.G.C. is a coinventor on the International Patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies that specifically bind IL-1α to reduce various sequelae of ischaemia-reperfusion injury to the central nervous system. G.G.C. is a consultant to Sovida Solutions Limited."

"Funding This project was supported by the joint Swiss National Science Foundation, Sino-Swiss Science and Technology Cooperation (SSSTC) (IZLCZ0_206081/1) supported by the National Natural Science Foundation of China (82161138026), Swiss National Science Foundation (SNF 310030_166576/1); and the Stiftung für Herz- und Kreislaufforschung (Foundation for Cardiovascular Research—Zurich Heart House,through the Heart Research Programme Sheikh Khalifa Bin Hamad Al Thani) and the Schweizerische Herzstiftung (Swiss Heart Foundation)."